Shobhit Seth

Shobhit Seth is a freelance financial writer, derivatives trader and consultant specializing in derivatives pricing and quantitative research. His career spans over 14 years as a Product Manager (Derivatives, Financial Data & Risk Management) at leading financial services companies across the UK, Europe, US and India. He has written extensively on topics pertaining to Derivatives Pricing, Derivatives Combinations & Structures, and Derivatives Trading Strategies. A lot of his work is available at www.FuturesOptionsETC.com, a site on Derivatives Trading which Shobhit owns and maintains. Shobhit also has expertise in index based products and ETFs, and he conducts training sessions on derivatives and related financial topics.

Shobhit has a Master’s degree in Financial Management (Specialization in Derivatives & Quantitative Research) from the Netherlands and a Bachelor of Technology degree (Electronics & Communications Engineering) from India.

  • Showing 1-15 of 873 items
  • 1
  • 2
  • 3
  • ...
  • 59
  • >>
  1. Stocks

    Supply Chain: The Big Leak Fueling High Drug Prices

    Non-manufacturing stakeholders in the drug pricing system are the ones contributing to high prices.
  2. Stocks

    United States Imports Only 25% of Its Drugs

    Despite increasing demands for local production, the US imports only a small portion of its drugs.
  3. Stocks

    Synergy Constipation Drug Gets FDA Approval (SGYP)

    Sales of Synergy's first FDA-approved drug could approach $350 million.
  4. Stocks

    Heron Declares $150 Million Public Offering (HRTX)

    Heron Therapeutics launched a $150 million common stock offering at $12.20 a share.
  5. Stocks

    Cytori to Buy Cancer Drug Co. Azaya for $170M (CYTX)

    Cytori expects to benefit from Azaya’s drug delivery platform and two high-potential cancer drugs.
  6. Stocks

    Dermira Up on Phase 3 Psoriasis Results (DERM)

    Dermira plans to file for marketing approval for its psoriasis drug Cimzia in the third quarter.
  7. Stocks

    FDA’s Biosimilar Guidelines May Force Longer Trials

    Biosimilars are set to face more stringent criteria, thanks to new FDA interchangeability guidelines.
  8. Stocks

    Atyr Pharma Spikes 33% on FDA Update (LIFE)

    Atyr Pharma said the FDA gave its Resolaris drug fast-track status and lifted a partial hold on a study.
  9. Stocks

    Biogen, Siemens Launch MS MRI Venture (BIIB, SIEGY)

    The collaboration aims to develop MRI tools to treat multiple sclerosis.
  10. Stocks

    Chuck E. Cheese IPO: Buy Shares in Your Childhood Memories

    Soon you'll be able to buy a few shares of your favorite childhood destination, as the established family entertainment chain ...
  11. Stocks

    McKesson Fined $150M for Opioid Reporting Violations (MCK)

    McKesson was fined $150 million for failing to report pharmacies' suspicious painkiller orders.
  12. Stocks

    Execs Suggest Way to Control Drug Prices (GILD)

    Two industry leaders suggest that government-run drug companies could limit price hikes.
  13. International / Global

    Many Drug Makers Are Abusing Orphan Drug Rules

    It may be the time to revamp the Orphan Drug Program amid concerns it's turning into a scam.
  14. Stocks

    FDA Approves Generic of Jazz’s Sleep Drug (JAZZ)

    Jazz Pharmaceuticals is set to face tough competition for its sleep disorder drug Xyrem.
  15. Stocks

    Alcobra Tanks 50% on Failed ADHD Study (ADHD)

    Alcobra’s only experimental ADHD drug failed a late-stage study, jeopardizing the company's future.
  • Showing 1-15 of 873 items
  • 1
  • 2
  • 3
  • ...
  • 59
  • >>